Author

Steve D. Gore

Observed names: Steve D Gore, Steve Gore

Institution: National Cancer Institute

Observed institutions: National Institutes of Health, St. Jude Children's Research Hospital, Johns Hopkins University, Vanderbilt University, National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center

OpenAlex ID: A5111599190

The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation

2004 · Jill Gilbert, Steve D. Gore, et al. · Clinical Cancer Research · 114

A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors

2009 · Jianqing Lin, Jill Gilbert, et al. · Clinical Cancer Research · 83

Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond.

2002 · Francisco Lo Coco, Arthur Zelent, et al. · PubMed · 20

S115: Consolidation With Blinatumomab Improves Overall and Relapse-free Survival in Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia: Impact of Age and Mrd Level in Ecog-acrin E1910

2023 · Mark Litzow, Zhuoxin Sun, et al. · HemaSphere · 18

Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)

2025 · Anuradha Krishnamurthy, Hong Wang, et al. · Cancer Chemotherapy and Pharmacology · 10

Myelodysplastic Syndromes: Pathophysiology

2010 · Steve D. Gore, Erica Warlick · 1

Corrigendum to “Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography” [J. Chromatogr. B 813(1) (2004) 81–88]

2016 · Ming Zhao, Michelle A. Rudek, et al. · Journal of Chromatography B

a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.

2007 · Ying Ye, Michael McDevitt, et al. · Blood

Works count: 8

Citation count: 246

H-index: 5

I10-index: 5